Gloucester Pharma Snags $29 Million Series D
As Gloucester Pharma preps for the FDA, the blood-borne cancer developer corrals a D round from Novo and others to gain leverage in partnering talks.
As Gloucester Pharma preps for the FDA, the blood-borne cancer developer corrals a D round from Novo and others to gain leverage in partnering talks.